The results from the 2018 Yunhuan Gao’s trial notes that lnc-chop would be expressed in MDSCs mediated by factors involved in inflammation and tumour development, while lnc-chop potentiates MDSCs immunosuppressive activity in vivo and in vitro. This evidence concerns the gene DDIT3 and neoplasm.